WNK-IN-11-d3

WNK-IN-11-d 3 is an orally active, selective and potent With-No-Lysine (WNK) kinase inhibitor. WNK-IN-11-d 3 is effective at regulating cardiovascular homeostasis. In Vivo WNK-IN-11 D3 (1.5 mg/kg; p.o.) shows an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability . WNK-IN-11 D3 (30 mg/kg; p.o.) shows significant reductions in systolic blood pressure (SBP) vs untreated mice . WNK-IN-11 D3 (0~100 mg/kg; p.o.) induces dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg . WNK-IN-11 D3 shows trends toward reduction of blood pressure, stroke volume, and total peripheral resistance, while increasing heart rate. WNK-IN-11 D3 shows efficacy in rodent models of hypertension and volume overload . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Sprague−Dawley rats Dosage: 1.5 mg/kg Administration: P.o. Result: Showed an improved rat PK profile, including lower clearance, improvement in absolute oral exposure, and a 2-fold improvement in oral bioavailability. Animal Model: FVB mice Dosage: 30 mg/kg Administration: P.o. Result: Showed significant reductions in systolic blood pressure (SBP) vs untreated mice. Animal Model: FVB mice Dosage: 0~100 mg/kg Administration: P.o. Result: Induced dose dependent diuresis, natriuresis, and kaliuresis, from 10 to 100 mg/kg. Form:Solid IC50& Target:WNK

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet